Novo Nordisk A/S , the largest manufacturer of diabetes products, encountered a smaller rise in revenue in 2014 for the second consecutive year as the impact of Obamacare continued to put pressure on price increase in the company’s largest market. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
